Dyadic International, Inc. (NASDAQ: DYAI) announced that the Japan Patent Office has allowed claims covering its proprietary Thermothelomyces heterothallica recombinant protein expression technology, according to a press release issued June 29, 2026.

The allowed claims cover novel aspects of Dyadic's C1 and Dapibus™ microbial production platforms, adding to the company's global intellectual property portfolio.

"This patent represents an important milestone in our strategy to expand Dyadic's intellectual property position and commercial opportunities in one of the world's most advanced biotechnology markets," said Joe Hazelton, Dyadic's President and Chief Operating Officer.

Dyadic also announced it has engaged Intralink, an international business development firm, to support expansion efforts in Japan and other markets. The engagement has produced discussions with prospective partners and customers across the biotechnology, pharmaceutical, food, nutrition, cosmetics, and industrial sectors.

Hazelton is scheduled to meet with existing and prospective partners during a business development visit to Japan in early July.

"Our collaboration with Intralink has accelerated business development efforts in Japan and helped establish meaningful discussions with organizations seeking flexible, scalable, and cost-effective protein production solutions," Hazelton added.

Dyadic's C1 and Dapibus™ platforms are designed for the production of recombinant proteins across markets including life sciences, food and nutrition, cosmetics, industrial enzymes, vaccines, and monoclonal antibodies.